AxoGen (AXGN) AI Stock Analysis

• Market Cap: $1.10B
• Dividend Yield: N/A
• Average Volume (3M): 927.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: 18.72%
• EPS Growth: 85.77%
• Country: US
• Employees: 451
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.12
• Shares Outstanding: 46,122,288
• 10 Day Avg. Volume: 1,122,640
• 30 Day Avg. Volume: 927,609
• PEG Ratio: 1.33
• Price to Book (P/B): 7.02
• Price to Sales (P/S): 3.89
• P/FCF Ratio: 66.31K
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 4.21
• Enterprise Value/Gross Profit: 5.63
• Enterprise Value/Ebitda: 69.35
• 1Y Price Target: $26.75
• Price Target Upside: 12.54% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): 0.27
• Revenue Forecast (FY): $219.72M

• Rating: 61 Neutral
• Price Target: $23.50 ▼(-1.14% Downside)

AxoGen's overall stock score is driven by strong earnings call results and positive technical indicators, indicating bullish momentum. However, financial performance concerns, particularly in profitability and cash flow, along with valuation challenges, weigh down the score.

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding market adoption and successful sales strategies, enhancing AxoGen's competitive position in nerve repair solutions.

Gross Margin Improvement

Improved gross margins reflect efficient cost management and operational effectiveness, contributing to better profitability potential over time.

Increased Coverage and Reimbursement

Expanded insurance coverage enhances product accessibility, potentially driving higher sales and market penetration in the long term.

Negative Factors

Profitability Challenges

Persistent profitability issues may hinder AxoGen's ability to reinvest in growth and innovation, affecting long-term financial health.

Cash Flow Challenges

Declining cash flow growth indicates potential liquidity issues, which could constrain operational flexibility and investment capacity.

Extended BLA Approval Timeline

Delays in regulatory approval for Avance Nerve Graft may impact market exclusivity and revenue potential, introducing uncertainty in strategic planning.

AxoGen Business Overview & Revenue Model

Company Description

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

How the Company Makes Money

AxoGen generates revenue primarily through the sale of its nerve repair products to hospitals and surgical centers. Their revenue model is based on the direct sales of their core products, which are used in various surgical procedures, particularly in the fields of orthopedics, plastic surgery, and neurosurgery. The company also benefits from reimbursement from insurance providers for its products, which makes them more accessible to healthcare providers and patients. Significant partnerships with healthcare institutions and participation in clinical studies further enhance their product visibility and credibility, contributing to increased sales. Additionally, AxoGen invests in research and development to innovate and expand its product offerings, aiming to capture a larger share of the growing market for nerve repair solutions.

AxoGen Financial Statement Overview

Summary

AxoGen's financial performance shows positive revenue growth and improved cash flow management, but profitability challenges persist with negative net income and return on equity. The balance sheet is strong with low leverage, providing a solid foundation for future growth.

Income Statement

AxoGen's income statement shows a positive revenue growth trend with a 4.5% increase in TTM, indicating a steady demand for its products. However, the company is still facing profitability challenges, as evidenced by the negative net profit margin of -2.3% in TTM. The gross profit margin remains strong at 74.3%, suggesting efficient production processes. The EBIT and EBITDA margins have improved, but remain low, indicating ongoing operational challenges.

Balance Sheet

The balance sheet reflects a stable financial position with a low debt-to-equity ratio of 0.18 in TTM, indicating conservative leverage. However, the return on equity is negative at -4.4%, highlighting profitability issues. The equity ratio is healthy, suggesting a strong asset base relative to liabilities.

Cash Flow

Cash flow analysis reveals significant improvement in free cash flow growth at 278.5% in TTM, indicating better cash management. The operating cash flow to net income ratio is 0.29, showing moderate cash generation relative to earnings. However, the free cash flow to net income ratio of 0.77 suggests that cash flow is not yet fully supporting profitability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	214.71M	187.34M	159.01M	138.58M	127.36M	112.30M
Gross Profit	160.52M	141.98M	127.87M	114.44M	104.43M	90.72M
EBITDA	13.03M	6.08M	-13.33M	-23.47M	-20.89M	-19.27M
Net Income	-2.10M	-9.96M	-21.72M	-28.95M	-26.98M	-23.79M
Balance Sheet
Total Assets	216.40M	203.73M	196.83M	195.39M	208.02M	201.38M
Cash, Cash Equivalents and Short-Term Investments	23.90M	33.48M	31.02M	48.79M	84.09M	103.97M
Total Debt	19.75M	68.69M	69.29M	67.43M	67.45M	54.63M
Total Liabilities	95.59M	99.82M	101.16M	94.39M	95.47M	78.23M
Stockholders Equity	120.81M	103.91M	95.67M	101.00M	112.55M	123.15M
Cash Flow
Free Cash Flow	3.20M	11.00K	-20.63M	-37.32M	-41.80M	-32.22M
Operating Cash Flow	6.51M	4.54M	-5.72M	-16.07M	-13.40M	-9.63M
Investing Cash Flow	-10.17M	-10.30M	19.25M	-3.20M	-23.65M	-16.96M
Financing Cash Flow	6.90M	2.29M	1.95M	1.79M	20.45M	40.47M

AxoGen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 23.77
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AXGN, the sentiment is Positive. The current price of 23.77 is above the 20-day moving average (MA) of 18.46, above the 50-day MA of 17.44, and above the 200-day MA of 15.47, indicating a bullish trend. The MACD of 1.63 indicates Negative momentum. The RSI at 81.12 is Negative, neither overbought nor oversold. The STOCH value of 93.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AXGN.

AxoGen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVS	66 Neutral	$624.23M	-1,020.27	-0.10%	―	5.08%	99.38%
AXGN	61 Neutral	$1.10B	―	-1.90%	―	18.72%	85.77%
SIBN	57 Neutral	$662.21M	-27.26	-14.18%	―	22.93%	43.83%
OFIX	52 Neutral	$587.28M	-4.68	-24.63%	―	4.84%	0.85%
AVNS	52 Neutral	$524.35M	―	-46.17%	―	1.48%	-6091.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNDM	46 Neutral	$1.03B	―	-111.91%	―	25.84%	-47.67%

AxoGen Corporate Events

Axogen Reports Strong Q3 2025 Results, Raises Guidance

Axogen, Inc. is a leading company in the development and commercialization of technologies for peripheral nerve regeneration and repair, providing innovative solutions to restore nerve function and improve quality of life for patients with peripheral nerve injuries. In its third-quarter 2025 earnings report, Axogen announced a significant revenue increase of 23.5% compared to the same period in 2024, reaching $60.1 million. The company also reported a net income of $0.7 million, marking a turnaround from a net loss in the previous year. Axogen’s gross margin improved to 76.6%, and adjusted EBITDA rose to $9.2 million, reflecting strong operational performance. Key highlights include the recognition of nerve allografts as a standard medical practice by major surgical societies and expanded insurance coverage, which now includes 18.1 million additional lives. The FDA’s anticipated approval of the Avance Nerve Graft BLA in December 2025 is expected to further bolster the company’s market position. Looking ahead, Axogen has raised its full-year revenue guidance to at least 19% growth, or $222.8 million, and expects to maintain a gross margin between 73% and 75%, despite one-time costs associated with regulatory approvals. The company remains optimistic about its growth trajectory and its mission to establish peripheral nerve repair as a standard of care.

AxoGen’s Earnings Call Highlights Robust Growth and Strategic Progress

AxoGen’s recent earnings call conveyed a generally positive sentiment, underscored by robust revenue growth and improved operational performance across all target markets. The company reported increased adoption and favorable gross margin trends, although it faced challenges in meeting high potential account goals and experienced an extended timeline for BLA approval. Despite these hurdles, the overall outlook remains optimistic due to strong financial results and strategic advancements.

Axogen Reports Q3 2025 Revenue Growth of 23.5%

On October 29, 2025, Axogen, Inc. reported its third quarter 2025 financial results, highlighting a revenue increase of 23.5% to $60.1 million compared to the same quarter in 2024. The company also raised its full-year revenue guidance to at least 19% growth, or $222.8 million. The quarter saw significant developments, including new position statements from medical societies recognizing nerve allografts as standard practice and expanded coverage for nerve repair, which validate Axogen’s market strategy. The FDA’s anticipated approval of the Avance® Nerve Graft BLA by December 2025 is expected to further bolster the company’s position in the industry.

The most recent analyst rating on (AXGN) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.

AxoGen’s Avance Nerve Graft Study: A Potential Game-Changer in Nerve Repair

AxoGen’s ongoing clinical study, officially titled ‘A Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair,’ aims to evaluate the real-world use, response rates, and safety of the Avance Nerve Graft. This registry study is significant as it seeks to provide comprehensive data on the effectiveness of Avance Nerve Graft in peripheral nerve injury repair, potentially influencing future treatment protocols.

FDA Extends Review for AxoGen’s Avance Nerve Graft

On August 22, 2025, Axogen, Inc. announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for the Avance® Nerve Graft by three months to December 5, 2025. This extension follows the FDA’s classification of Axogen’s recent submission of new manufacturing and facility information as a Major Amendment, necessitating additional review time. The FDA also plans to provide feedback on product labeling in November 2025. This development is significant for Axogen as it continues to transition Avance Nerve Graft from a tissue product to a BLA-approved biologic, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (AXGN) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.

Axogen, Inc. Reports Strong Revenue Growth in Q2 2025

Axogen, Inc. is a leading company in the development and commercialization of technologies for peripheral nerve regeneration and repair, offering innovative solutions for restoring nerve function and improving patients’ quality of life. In its latest earnings report, Axogen announced a significant increase in revenue and raised its full-year revenue guidance, reflecting strong market performance and strategic execution. The company reported second-quarter revenue of $56.7 million, marking an 18.3% increase from the previous year, with a net income of $0.6 million compared to a net loss in the same quarter last year. Axogen also achieved a gross margin improvement and expanded its market coverage, including an increase in covered lives for nerve repair reimbursement. Looking ahead, Axogen remains optimistic about its strategic priorities and anticipates continued growth, supported by its market development strategies and the potential approval of its Avance Nerve Graft by the FDA.

AxoGen’s Earnings Call: Strong Growth Amid Challenges

AxoGen’s recent earnings call conveyed a generally positive outlook, underscored by robust revenue growth and strategic execution in high potential accounts and clinical training. Despite these positive developments, there were concerns about gross margin pressure and uncertainties related to logistics following BLA approval.

Axogen Reports Strong Q2 2025 Financial Results

On August 5, 2025, Axogen, Inc. reported its financial results for the second quarter of 2025, showcasing a significant revenue increase of 18.3% compared to the same period in 2024. The company also raised its full-year revenue guidance to at least 17% growth, or $219 million, reflecting strong market development strategies and commercial execution. The quarter saw broad-based revenue growth across all markets, including Extremities, Oral Maxillofacial & Head and Neck, and Breast. Additionally, Axogen expanded coverage and reimbursement for nerve repair, adding approximately 10 million new covered lives in 2025. The U.S. FDA accepted the company’s Biologics License Application for Avance® Nerve Graft, with a goal date for approval set for September 5, 2025.

The most recent analyst rating on (AXGN) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on AxoGen stock, see the AXGN Stock Forecast page.